|ANI Pharmaceuticals -- USA Stock|| |
USD 59.97 0.67 1.10%
CEO and President and Director
Mr. Arthur S. Przybyl is President, Chief Executive Officer, Director of the Company
Age: 59 CEO Since 2013
Przybyl is an experienced healthcare executive in a career that spans over 25 years and includes the management of both specialty pharmaceutical and medical device companies. From August 2002 through January 2009, Mr. Przybyl served as President and Chief Executive Officer of Akorn, Inc., a NASDAQlisted specialty pharmaceutical company that manufactures and markets ophthalmic, liquid and lyophilized injectable, and vaccine drug products. Prior to Akorn, Mr. Przybyl was President of privatelyheld company Hearing Innovations, Inc. and President and Chief Operating Officer of NASDAQlisted company Bioject, Inc., both of which are medical device companies. During his career, Mr. Przybyl has held several sales and marketing management positions, including Senior Vice President, Sales and Marketing for International Medication Systems, Inc. and Director, Corporationrationrationrate Marketing and National Accounts for LyphoMed, Inc., both specialty pharmaceutical companies.
Arthur Przybyl Latest Insider Activity
The company has return on total asset (ROA)
of 6.74 %
which means that it generated profit of $6.74 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE)
of (0.63) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 201.51 M in liabilities with Debt to Equity (D/E) ratio of 115.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. ANI Pharmaceuticals has Current Ratio of 3.29 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota. ANI Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 173 people.ANI Pharmaceuticals (ANIP) is traded on NASDAQ General Markets in USA. It is located in MINNESOTA, U.S.A and employs 173 people. ANI Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
ANI Pharmaceuticals Leadership Team
|Robert Brown, Chairman, MBA|
|Charlotte Arnold, President, MBA|
|Mark Ginski, President, Ph.D|
|Robert Schrepfer, VP, MBA|
|Daniel Raynor, Director|
|Stephen Carey, President|
|David Sullivan, VP, Ph.D|
|Karen Quinn, President|
|James Marken, VP|
|Peter Lankau, Director|
|Fred Holubow, Director|
|Tracy Marshbanks, Director|
|Arthur Przybyl, CEO|
|Thomas Penn, Director|
Stock Performance Indicators
Most of Macroaxis users are presently bullish on ANI Pharmaceuticals. What is your sentiment towards investing in ANI Pharmaceuticals? Are you bullish or bearish?
The main assumption in equity investing is that a higher degree of volatility (or risk) means a higher potential (or expected) return on investment. Conversely, investors who take on a low degree of risk have a low expection for return.
You can create optimal portfolios in USA market or optimize your existing portfolio in one of two ways: 1)
For any level of risk, select the one which has the highest expected return. 2)
For any expected return, select the one which has the lowest volatility.